Bcwm LLC Grows Stock Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Bcwm LLC increased its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 6.4% in the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 19,993 shares of the medical equipment provider’s stock after acquiring an additional 1,209 shares during the period. Bcwm LLC’s holdings in Zimmer Biomet were worth $2,170,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. OLD Point Trust & Financial Services N A acquired a new stake in shares of Zimmer Biomet during the 4th quarter worth about $26,000. Ables Iannone Moore & Associates Inc. purchased a new stake in Zimmer Biomet during the fourth quarter worth about $30,000. Crewe Advisors LLC acquired a new stake in Zimmer Biomet during the 1st quarter worth approximately $31,000. Family Firm Inc. purchased a new position in Zimmer Biomet in the 2nd quarter valued at approximately $33,000. Finally, J.Safra Asset Management Corp grew its stake in shares of Zimmer Biomet by 712.1% in the first quarter. J.Safra Asset Management Corp now owns 268 shares of the medical equipment provider’s stock worth $35,000 after acquiring an additional 235 shares in the last quarter. Institutional investors and hedge funds own 88.89% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently issued reports on ZBH shares. Canaccord Genuity Group reduced their price objective on Zimmer Biomet from $120.00 to $115.00 and set a “hold” rating on the stock in a research note on Tuesday, September 10th. Robert W. Baird lowered their price objective on Zimmer Biomet from $155.00 to $145.00 and set an “outperform” rating for the company in a research report on Thursday, August 8th. Citigroup reduced their target price on shares of Zimmer Biomet from $134.00 to $120.00 and set a “neutral” rating on the stock in a report on Wednesday, July 10th. The Goldman Sachs Group started coverage on shares of Zimmer Biomet in a report on Thursday, May 30th. They set a “neutral” rating and a $129.00 price target for the company. Finally, Piper Sandler lowered shares of Zimmer Biomet from an “overweight” rating to a “neutral” rating and reduced their price objective for the company from $140.00 to $115.00 in a report on Monday, July 1st. Two analysts have rated the stock with a sell rating, twelve have given a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $125.44.

Zimmer Biomet Stock Performance

Shares of ZBH opened at $106.26 on Monday. The company has a market capitalization of $21.64 billion, a PE ratio of 23.00, a P/E/G ratio of 1.92 and a beta of 1.02. Zimmer Biomet Holdings, Inc. has a 52-week low of $102.00 and a 52-week high of $133.90. The company has a 50-day simple moving average of $109.90 and a 200-day simple moving average of $116.03. The company has a quick ratio of 0.63, a current ratio of 1.29 and a debt-to-equity ratio of 0.31.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings results on Wednesday, August 7th. The medical equipment provider reported $2.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.99 by $0.02. The business had revenue of $1.94 billion during the quarter, compared to the consensus estimate of $1.94 billion. Zimmer Biomet had a return on equity of 12.86% and a net margin of 13.25%. The business’s revenue was up 3.9% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.82 EPS. Equities research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.02 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, October 31st. Investors of record on Monday, September 30th will be given a dividend of $0.24 per share. The ex-dividend date of this dividend is Monday, September 30th. This represents a $0.96 annualized dividend and a dividend yield of 0.90%. Zimmer Biomet’s dividend payout ratio is currently 20.78%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.